Startseite Synthesis and crystal structure of ethyl (2S,4aS,6aS,6bR,8aR,12aS,12bR,14bR,E)-10-(((3,4-dichlorobenzyl)oxy)imino)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylate
Artikel Open Access

Synthesis and crystal structure of ethyl (2S,4aS,6aS,6bR,8aR,12aS,12bR,14bR,E)-10-(((3,4-dichlorobenzyl)oxy)imino)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylate

  • Zhang-Chao Dong ORCID logo , Hui Shen , Ze-Bo Mu EMAIL logo und Kai-Hua Xu
Veröffentlicht/Copyright: 13. Januar 2025

Abstract

C39H53Cl2NO4, monoclinic, P21 (no. 4), a = 7.55730(10) Å, b = 11.0989(2) Å, c = 20.9222(3) Å, β = 91.426(1)°, V = 1754.36(5) Å3, Z = 2, R gt (F) = 0.0360, wR ref (F2) = 0.1028, T = 169.98(10) K.

CCDC no.: 2383172

Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

Table 1:

Data collection and handling.

Crystal: Colourless block
Size: 0.14 × 0.12 × 0.10 mm
Wavelength: Cu Kα radiation (1.54184 Å)
μ: 1.99 mm−1
Diffractometer, scan mode: XtaLAB AFC12 (RINC), ω
θmax, completeness: 71.6°, >99 %
N(hkl)measured, N(hkl)unique, Rint: 8505, 4877, 0.023
Criterion for Iobs, N(hkl)gt: Iobs > 2σ(Iobs), 4,771
N(param)refined: 423
Programs: CrysAlisPRO, 1 Olex2, 2 SHELX 3
Table 2:

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

Atom x y z Uiso*/Ueq
Cl1 1.22096 (10) 0.45274 (9) 0.02981 (4) 0.0476 (2)
Cl2 0.92423 (11) 0.27093 (10) −0.01693 (4) 0.0540 (3)
O1 0.5716 (3) 0.5090 (2) 0.91306 (8) 0.0337 (5)
O2 0.7056 (3) 0.5477 (3) 0.82164 (10) 0.0473 (6)
O3 0.5548 (2) 0.4603 (2) 0.23300 (8) 0.0326 (5)
O43 0.5947 (3) 0.6898 (2) 0.54171 (9) 0.0352 (5)
N1 0.3814 (3) 0.4549 (2) 0.25845 (10) 0.0287 (5)
C1 0.1911 (3) 0.4970 (3) 0.83571 (12) 0.0270 (6)
H1A 0.246862 0.565829 0.858566 0.032*
H1B 0.071309 0.486097 0.852884 0.032*
C2 0.2996 (4) 0.3838 (3) 0.85056 (12) 0.0278 (6)
H2A 0.236129 0.312554 0.833108 0.033*
H2B 0.311565 0.373812 0.897487 0.033*
C3 0.4843 (4) 0.3900 (3) 0.82202 (12) 0.0278 (6)
C4 0.4626 (3) 0.4106 (3) 0.74942 (12) 0.0261 (6)
H4A 0.402696 0.339809 0.729909 0.031*
H4B 0.581218 0.417272 0.730731 0.031*
C5 0.3549 (3) 0.5250 (2) 0.73244 (11) 0.0215 (5)
H5 0.424357 0.594957 0.749783 0.026*
C6 0.3420 (3) 0.5418 (2) 0.66026 (11) 0.0204 (5)
C7 0.4691 (3) 0.6044 (3) 0.63163 (12) 0.0259 (5)
H7 0.559667 0.638690 0.658165 0.031*
C8 0.4795 (3) 0.6241 (3) 0.56241 (12) 0.0246 (5)
C9 0.3438 (3) 0.5567 (2) 0.52042 (11) 0.0192 (5)
H9 0.385193 0.471156 0.521125 0.023*
C10 0.1632 (3) 0.5541 (2) 0.55581 (11) 0.0184 (5)
C11 0.1925 (3) 0.4820 (2) 0.62060 (11) 0.0186 (5)
C12 0.0192 (3) 0.4738 (2) 0.65835 (11) 0.0226 (5)
H12A −0.042582 0.552393 0.655410 0.027*
H12B −0.058785 0.412680 0.637794 0.027*
C13 0.0462 (3) 0.4411 (3) 0.72908 (11) 0.0228 (5)
H13A 0.095249 0.358533 0.732407 0.027*
H13B −0.069798 0.441469 0.750035 0.027*
C14 0.1722 (3) 0.5293 (2) 0.76438 (11) 0.0226 (5)
C15 0.0985 (4) 0.6574 (3) 0.75963 (13) 0.0294 (6)
H15A 0.171299 0.711416 0.786357 0.044*
H15B −0.023570 0.658249 0.774421 0.044*
H15C 0.100347 0.684479 0.715079 0.044*
C16 0.0196 (3) 0.4917 (3) 0.51401 (11) 0.0224 (5)
H16A 0.039965 0.403638 0.515191 0.027*
H16B −0.097453 0.507371 0.532580 0.027*
C17 0.0150 (3) 0.5332 (3) 0.44461 (11) 0.0229 (5)
H17A −0.015482 0.619889 0.442541 0.027*
H17B −0.077167 0.487882 0.420289 0.027*
C18 0.1954 (3) 0.5127 (2) 0.41452 (11) 0.0191 (5)
H18 0.228143 0.428016 0.426108 0.023*
C19 0.3394 (3) 0.5920 (2) 0.44791 (11) 0.0207 (5)
C20 0.3104 (4) 0.7280 (3) 0.43733 (12) 0.0251 (5)
H20A 0.183825 0.746359 0.439429 0.038*
H20B 0.353531 0.750794 0.395240 0.038*
H20C 0.375317 0.773218 0.470584 0.038*
C21 0.5187 (3) 0.5533 (3) 0.41996 (12) 0.0256 (6)
H21A 0.614015 0.603166 0.439659 0.031*
H21B 0.542216 0.468362 0.431825 0.031*
C22 0.5257 (3) 0.5654 (3) 0.34741 (12) 0.0286 (6)
H22A 0.527805 0.651960 0.336123 0.034*
H22B 0.637056 0.528850 0.332728 0.034*
C23 0.3725 (3) 0.5066 (2) 0.31268 (11) 0.0221 (5)
C24 0.1866 (3) 0.5143 (2) 0.33965 (11) 0.0212 (5)
C25 0.0989 (4) 0.6285 (3) 0.31102 (12) 0.0270 (6)
H25A 0.172689 0.698854 0.321167 0.040*
H25B −0.018323 0.639304 0.329214 0.040*
H25C 0.086542 0.619766 0.264511 0.040*
C26 0.0785 (4) 0.4052 (3) 0.31627 (13) 0.0283 (6)
H26A 0.079646 0.401576 0.269484 0.042*
H26B −0.043792 0.413118 0.330233 0.042*
H26C 0.130538 0.331333 0.334164 0.042*
C27 0.5463 (4) 0.3951 (3) 0.17481 (13) 0.0360 (7)
H27A 0.446940 0.425252 0.147555 0.043*
H27B 0.525544 0.308616 0.183596 0.043*
C28 0.7181 (4) 0.4104 (3) 0.14076 (12) 0.0291 (6)
C29 0.8468 (4) 0.4922 (3) 0.15981 (12) 0.0336 (7)
H29 0.829059 0.540555 0.196553 0.040*
C30 1.0028 (4) 0.5049 (3) 0.12586 (14) 0.0391 (7)
H30 1.091000 0.560662 0.139838 0.047*
C31 1.0279 (4) 0.4360 (3) 0.07190 (13) 0.0341 (6)
C32 0.8986 (4) 0.3559 (3) 0.05178 (13) 0.0339 (7)
C33 0.7457 (4) 0.3416 (3) 0.08639 (14) 0.0328 (6)
H33 0.659166 0.284371 0.072806 0.039*
C34 0.5866 (4) 0.2714 (3) 0.83429 (14) 0.0384 (7)
H34A 0.704425 0.277394 0.816008 0.058*
H34B 0.521803 0.204337 0.814222 0.058*
H34C 0.598526 0.257302 0.880438 0.058*
C35 0.5976 (3) 0.4912 (3) 0.85078 (12) 0.0284 (6)
C36 0.6850 (4) 0.5996 (3) 0.94329 (15) 0.0381 (7)
H36A 0.685753 0.673708 0.916977 0.046*
H36B 0.807818 0.569099 0.947610 0.046*
C37 0.6133 (4) 0.6264 (3) 1.00800 (14) 0.0368 (7)
H37A 0.494102 0.660422 1.003088 0.055*
H37B 0.690813 0.684488 1.030198 0.055*
H37C 0.608298 0.551855 1.032983 0.055*
C38 0.0998 (3) 0.6839 (2) 0.56950 (12) 0.0243 (5)
H38A −0.015326 0.681079 0.589987 0.036*
H38B 0.088556 0.728677 0.529228 0.036*
H38C 0.186057 0.724252 0.597969 0.036*
C44 0.2531 (3) 0.3506 (2) 0.60832 (12) 0.0240 (5)
H44A 0.376569 0.350597 0.595047 0.036*
H44B 0.178098 0.314700 0.574506 0.036*
H44C 0.242953 0.303395 0.647658 0.036*

1 Source of material

An amount of 1 mmol of glycyrrhetinic acid was dissolved in THF. Then, 4.8 mmol of Jones reagent was added and reacted at 0 °C. After that, column chromatography purification was carried out. The obtained compound was dissolved in DMF, and potassium iodide, potassium carbonate and bromoethane were added. The mixture was stirred at room temperature for 6 h. The obtained compound was purified by column chromatography again. The obtained clean compound was dissolved in ethanol, hydroxylamine hydrochloride and sodium bicarbonate were added, and refluxed at 90 °C for 14 h. After purification, the obtained compound was dissolved in THF. NaH was added under ice-water bath and stirred for 3 h. Then, 3,4-dichlorobenzyl bromide was added and stirred at room temperature for 15 h. Finally, methanol was added for inactivation, and then purification was carried out to obtain the compound.

2 Comment

Glycyrrhetinic acid is an effective component extracted from the traditional medicinal and edible plant licorice. Compounds obtained by further structural modification of glycyrrhetinic acid have multiple activities and are the focus of people’s research recently. 4 , 5 , 6 Glycyrrhetinic acid has a variety of pharmacological activities, such as anti-inflammatory, anti-tumor, and anti-free radical. 7

The target compound is composed of five six-membered rings connected to a benzene ring through an oxygen atom and a nitrogen atom. There are two chlorine atoms connected to the phenyl ring. The bond lengths and bond angles are within the normal range of the title structure and are consistent with the previous reported range. The first keto group was confirmed by the distance of 1.223(3) Å (C8–O43). The second keto group was confirmed by the distance of 1.206(4) Å (C35–O2), and the carbon and nitrogen are identified by a distance of 1.428(3) Å (N3–O1), respectively.


Corresponding author: Ze-Bo Mu, Guizhou Xin Zihong Pharmaceutical Excipients Co., Ltd, Danzhai, 557599, P.R. China, E-mail:

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: Guizhou Provincial Science and Technology Projects (Qian Ke He Cheng Guo [2019] 4408).

  3. Conflict of interest: The authors declare no conflicts of interest regarding this article.

References

1. Rigaku, O. D. CrysAlisPro Software; Rigaku Oxford Diffraction Japan, 2015.Suche in Google Scholar

2. Dolomanov, O. V.; Bourhis, L. J.; Gildea, R. J.; Howard, J. A. K.; Puschmann, H. Olex2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341; https://doi.org/10.1107/s0021889808042726.Suche in Google Scholar

3. Sheldrick, G. M. Crystal Structure Refinement with Shelxl. Acta Crystallogr. 2015, C71, 3–8; https://doi.org/10.1107/s2053229614024218.Suche in Google Scholar

4. Fuqing, Y.; Ju, L.; Yang, L. Research Progress of Liver Cancer Targeted Nano-Delivery System Based on Glycyrrhetinic Acid. Chin. Pharm. J. 2024, 59, 1065–1073.Suche in Google Scholar

5. Mohong, F.; Xiaoy, W.; Xiaomei, Z. Synthesis and Antitumor Activity of 2,3-Dihydroxy-Glycyrrhetinic Acid Esters. Contemp. Chem. Ind. 2023, 52, 1865–1868.Suche in Google Scholar

6. Jun, D.; Hai, X.; Feng, S. Intervention Effect of 18β-Glycyrrhetinic Acid on K19–C2mE Spontaneous Gastric Tumor Transgenic Mice and its Influence on the Expression of COX-2 and IL-1β. Hebei Med. J. 2023, 45, 353–356.Suche in Google Scholar

7. Feng, G.; Fei, Z.; Hongshan, C. Design, Synthesis and Activity Evaluation of Antitumor Derivatives of Glycyrrhetinic Acid. Northwest Pharm. J. 2021, 36, 789–796.Suche in Google Scholar

Received: 2024-10-23
Accepted: 2024-12-02
Published Online: 2025-01-13
Published in Print: 2025-04-28

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Frontmatter
  2. New Crystal Structures
  3. The crystal structure of N-(3-bromo-4-fluorophenyl)-N′-hydroxy-4-{[2-(4-methylphenyl)ethyl]amino}-1,2,5-oxadiazole-3-carboximidamide, C18H17BrFN5O2
  4. Synthesis and crystal structure of ethyl (2S,4aS,6aS,6bR,8aR,12aS,12bR,14bR,E)-10-(((3,4-dichlorobenzyl)oxy)imino)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylate
  5. The crystal structure of pyrazole nitrate
  6. Crystal structure of tetramethyl-bis(μ2-2-(2-hydroxy-3-methoxybenzylidene)-1-(6-(2-(2-hydroxy-3-methoxybenzylidene)hydrazine-1-carbonyl)picolinoyl)hydrazin-1-ido-κ4O,N,O′:O′)ditin(II) ─ ethanol (1/2), C54H62N10O14Sn2
  7. Crystal structure of catena-poly[μ3-iodido-(4-bromopyridine-κ1N)copper(I)], C5H4BrNCuI
  8. The crystal structure of cyclopentadienyl Co–P–C complexes by benzylideneacetone addition, C38H38CoO2P
  9. Synthesis and crystal structure of-(3S,10S,13S,17S)-N-(2-methoxyphenyl)-10,13-dimethyl-17-((R)-1-(phenylamino)ethyl)hexadecahydro-1H-cyclopenta[α]phenanthren-3-amine, C34H48N2O
  10. The crystal structure of (E)-3-((E)-3-(4-ethoxy-3-methoxyphenyl)-1-hydroxyallylidene) chroman-2,4-dione, C21H18O6
  11. The crystal structure of trans–L/D-[bis-(2-methyl-8-hydroxyquinoline-κ2 N,O) bis-(1,3,5-triaza-7-phosphaadamantane-κ2 P)cobalt(III)] tetrafluoroborate
  12. Crystal structure of 9-chloro-2,3,4,4a,5,6-hexahydro-1H-pyrido [1′,2′:1,6]pyrazino[2,3-b]quinoxaline, C14H15ClN4
  13. Crystal structure of 7-(diethylamino)-3-(benzoyl)-2 H -chromen-2-one, C20H19NO3
  14. The crystal structure of 4–bromo-3,5-dinitropyrazole
  15. Crystal structure of 8-hydroxy-3,5,8a-trimethyl-7,8,8a,9-tetrahydronaphtho[2,3-b]furan-4,6-dione, C15H16O4
  16. Crystal structure of 5-hydroxy-3,5,8a-trimethyl-4a,5,6,7,8a,9-hexahydronaphtho[2,3-b]furan-4,8-dione, C15H18O4
  17. Synthesis and crystal structure of-(3S,10S,13S,17S)-N-(2-methoxyphenyl)-10,13-dimethyl-17-((R)-1-(p-tolylamino)ethyl)hexadecahydro-1H-cyclopenta[α]phenanthren-3-amine, C35H50N2O
  18. The crystal structure of catena-poly((μ2-1,3,5-tri(1H- imidazol-1-yl)benzene κ2N:N′)-bis(4-hydroxbenzoato-κ1O)-zinc(II) monohydrate), C29H24N6O7Zn
  19. Crystal structure of 2-(benzo[d]oxazol-2-yl)acetonitrile, C9H6N2O
  20. Crystal structure of 1,3-dihydroxy-6,8-dimethoxy-2-(6-methyltetrahydro-2Hpyran-2-yl)-4a,9a-dihydroanthracene-9,10-dione, C22H22O7
  21. The crystal structure of the double salt potassium 1-methylpiperazine-1,4-di-ium trinitrate, C5H14KN5O9
  22. Crystal structure of 5′-hydroxy-6′-methoxy-1′-methyl-2′,3′,8′,8a′-tetrahydro-1′H-spiro[cyclohexane-1,7′-cyclopenta[ij]isoquinoline]-2,5-dien-4-one, C18H19NO3
  23. The crystal structure of 1,1′-(2,3,5,6-tetramethylpyrazine-1,4-diyl)bis(ethan-1-one), C12H18N2O2
  24. Crystal structure of [μ2-piperazine-1,4-bis(2-hydroxypropanesulfonato-κ2O:O′)] bis(μ2-4,4′-trimethylenedipyridyl-κ2N:N′)disilver(I), C18H24AgN3O4S
  25. Crystal structure of bis ((1-((E)-((4-methoxyphenyl)imino)methyl)naphthalen-2-yl)oxy) copper(II), C36H28CuN2O4
  26. Synthesis and crystal structure of 6,6′-((1E,11E)-5,8-dioxa-2,11-diazadodeca-1,11-diene-1,12-diyl) bis(2,4-di-tert-butylphenol), C36H56N2O4
  27. The crystal structure of barium hexahydroxidoiridate(IV) dihydroxide, Ba2[Ir(OH)6](OH)2
  28. Crystal structure of cinnamoyl ferrocene, C19H16FeO
  29. Crystal structure of (E)-3-(4-butoxyphenyl)acryloylferrocene, C23H24FeO2
  30. Crystal structure of 7-(dimethylamino)-2-hydroxy-2-(trifluoromethyl)-2H-chromene-3-ethyl carboxylate, C15H16F3NO4
  31. The crystal structure of 1-phenylethan-1-aminium 4-hydroxy-3,5-dimethoxybenzoate C17H21NO5
  32. The crystal structure of 1,3,5-trichloro-2-nitrobenzene
  33. The crystal structure of tris(μ2-bromido)-bis(η6-p-cymene)-diosmium(II) tetrafluoroborate, C20H28BBr3F4Os2
  34. Crystal structure of new barium lithium manganese fluorides: Ba14Li1.87Mn14.13F68 with a Jarlite–related structure
  35. Crystal structure of (4-fluorobenzyl)triphenylphosphonium chloride, C25H21ClFP
  36. The crystal structure of calcitriol–chloroform (1/1), C27H44O3⋅CHCl3
  37. The crystal structure of (E)-1-((3)-nitrophenyl)pyren-3-(pyren-1-yl)prop-2-en-1-one, C25H15NO3
  38. Crystal structure of (E)-2-hydroxy-N′-(1-(4-hydroxyphenyl)propylidene)benzohydrazide, C16H16N2O3
  39. Crystal structure of (E)-(3-(thiophen-2-yl)acryloyl)ferrocene, C17H14FeOS
  40. Crystal structure of (E)-(3-(furan-2-yl)acryloyl)ferrocene, C17H14FeO2
  41. Synthesis and crystal structure poly[diaqua(μ3-3-(((7-hydroxy-3-(4-methoxy-3-sulfonatophenyl)-4-oxo-4H-chromen-8-yl) methyl)ammonio)propanoate-κ3 O:O′:O″) sodium(I)] monohydrate, C20H24NNaO12S
  42. Crystal structure of 9-methoxy-4-(2-methoxypyridin-3-yl)-5,6-dihydrobenzo[h]quinazolin-2-amine C19H18N4O2
  43. Synthesis and crystal structure of 4-(difluoromethyl)-1-methyl-N-(pyridin-3-yl)-1H-pyrazole-3-carboxamide hydrate, C11H12F2N4O2
  44. The crystal structure of caesalfurfuric acid B, C22H32O4
  45. The crystal structure of 2-bromo-2-(5-bromo-2-methyl-4-nitro-1H-imidazol-1-yl)-1-phenylethanone, C12H9Br2N3O3
  46. The crystal structure of bis{chlorido-[μ2-(1-oxidopyridin-2-yl)(pyridin-2-yl)amido-κ3 O,N, N′]copper(II)}, C20H16Cl2Cu2N6O2
  47. The crystal structure of 3-amino-2-formyl-1-phenyl-9,10-dihydrophenanthrene-4-carbonitrile, C22H16N2O
  48. The crystal structure of 1,1′-(2,5-dimethylpyrazine-1,4-diyl)bis(ethan-1-one), C10H14N2O2
  49. Crystal structure of 5′-(9-phenyl-9H-carbazol-3-yl)-[2,2′-bithiophene]-5-carbaldehyde, C27H17NOS2
  50. The crystal structure of the double salt dipyridin-1-ium bromide tribromide
  51. Crystal structure of (E)-(3-(3-methylthiophen-2-yl)acryloyl)ferrocene, C18H16FeOS
  52. Crystal structure of (E)-(3-(4-phenoxyphenyl)acryloyl)ferrocene, C25H20FeO2
  53. Crystal structure of (E)-(3-(3,4-dimethylphenyl)acryloyl)ferrocene, C21H20FeO
  54. Crystal structure of [(1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N′′,N‴)tetracyanidodiplatinum(II)] dimethyl sulfoxide solvate, C18H36N8O2Pt2S2
  55. Crystal structure of (4-ethoxybenzyl)triphenylphosphonium bromide ethanol solvate, C29H32BrO2P
  56. Crystal structure of (1-naphthalen-1-yl-methyl)triphenylphosphonium chloride ethanol solvate, C31H30ClOP
  57. Crystal structure of (1,4,8,11-tetraazacyclotetradecane-κ4N,N,N,N‴)platinum(II) bis[tribromido(dimethyl sulfoxide-κS)platinate(II)], C14H36Br6N4O2Pt3S2
  58. Crystal structure of (2-methylbenzyl)triphenylphosphonium chloride ethanol solvate, C28H30ClOP
  59. Crystal structure of bis(η2, σ1-8-methoxycyclooct-4-enyl)(μ2-1,4,8,11-tetraazacyclotetradecane-κ4 N, N, N, N‴)diplatinum(II) dibromide, C28H54Br2N4O2Pt2
  60. Crystal structure of (1,4,8,11-tetraazacyclotetradecane-κ4N,N,N,N)palladium(II) tetrabromidopalladate(II), C10H24Br4N4Pd2
  61. Crystal structure of (1,4,8,11-tetraazacyclotetradecane-κ4N,N,N,N‴)palladium(II) bis[trichlorido(dimethyl sulfoxide-κS)platinate(II)], C14H36Cl6N4O2PdPt2S2
  62. Crystal structure of (1,4,8,11-tetraazacyclotetradecane-κ4N,N′,N″,N‴)palladium(II) tetraiodidopalladate(II), C10H24I4N4Pd2
Heruntergeladen am 3.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2024-0381/html
Button zum nach oben scrollen